Currently Chief Scientific Officer at AKL Therapeutics Ltd (http://www.aklrd.com), a company that identifies secondary metabolites of plant origin with proven efficacy and safety, which are then synthesized before undergoing standard pharmaceutical clinical development.I am an experienced, commercially aware, broad based scientist who can rapidly assimilate knowledge in new therapeutic areas and apply this knowledge to provide strategic input into development of life cycle plans. I have excellent interactive and presentation skills with all functions in a multi-layered pharmaceutical company at all levels of seniority. Following a degree in Applied Biology at Brunel University, I worked at Glaxo before undertaking microbiology research at the Royal Free Hospital in London and the University of London School of Pharmacy. I then undertook various roles in Clinical Research at Ayerst/Wyeth, across a range of therapeutic areas including diabetes, CNS, gastroenterology, and inflammation, providing Strategic Scientific Support, Health Technology Assessment, and Clinical Trial design and strategy. I was project lead for all submissions to NICE for the biologic etanercept Following promotion to European Clinical Science Director Inflammation in 2006, I was responsible for:• Strategic scientific input into clinical, commercial and access programmes• Co-Chair of Optimisation Expert Panel and member of three other Expert Panels• Project lead for internal training programme• Membership of various global internal teams (Asset Teams, Publication strategy, investigator initiated protocol approval etc)Twice I was awarded the President's Achieving Excellence AwardFrom 2010 I undertook consultancy work for a number of companies involved in the pharmaceutical industry including Pfizer, Napp, UCB, and Norgine. I have authored one book chapter, 26 peer reviewed papers, 5 letters to and 45 abstracts